Search Results - "Guchelaar, Henk Jan"

Reply to: Temporary Like Achilles: Pre‐emptive germline pharmacogenetic testing by Guchelaar, Henk‐Jan, Swen, Jesse

Get full text

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group by Caudle, Kelly E., Sangkuhl, Katrin, Whirl‐Carrillo, Michelle, Swen, Jesse J., Haidar, Cyrine E., Klein, Teri E., Gammal, Roseann S., Relling, Mary V., Scott, Stuart A., Hertz, Daniel L., Guchelaar, Henk‐Jan, Gaedigk, Andrea

“…Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical…”
Get full text

Liposomal drug formulations in cancer therapy: 15 years along the road by Slingerland, Marije, Guchelaar, Henk-Jan, Gelderblom, Hans

“…Liposomes as pharmaceutical drug carriers were developed to increase antitumour efficacy and decrease drug toxicity. Doxorubicin HCl liposomal injection was…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy by Goetz, Matthew P., Sangkuhl, Katrin, Guchelaar, Henk‐Jan, Schwab, Matthias, Province, Michael, Whirl‐Carrillo, Michelle, Symmans, W. Fraser, McLeod, Howard L., Ratain, Mark J., Zembutsu, Hitoshi, Gaedigk, Andrea, van Schaik, Ron H., Ingle, James N., Caudle, Kelly E., Klein, Teri E.

“…Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the…”
Get full text

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines by Lunenburg, Carin A T C, van der Wouden, Cathelijne H, Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H, de Boer-Veger, Nienke J, Buunk, Anne Marie, Houwink, Elisa J F, Mulder, Hans, Rongen, Gerard A, van Schaik, Ron H N, van der Weide, Jan, Wilffert, Bob, Deneer, Vera H M, Swen, Jesse J, Guchelaar, Henk-Jan

“…Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to…”
Get full text

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? by Knikman, Jonathan E., Gelderblom, Hans, Beijnen, Jos H., Cats, Annemieke, Guchelaar, Henk‐Jan, Henricks, Linda M.

“…Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although most often well tolerated, severe toxicity is encountered in…”
Get full text

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review by Klomp, Sylvia D., Manson, Martijn L., Guchelaar, Henk-Jan, Swen, Jesse J.

“…Phenoconversion is the mismatch between the individual’s genotype-based prediction of drug metabolism and the true capacity to metabolize drugs due to…”
Get full text

Liver and kidney function in patients with Covid‐19 treated with remdesivir by Laar, Sylvia A., Boer, Mark G. J., Gombert‐Handoko, Kim B., Guchelaar, Henk‐Jan, Zwaveling, Juliette

“…For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and…”
Get full text

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time by Hulshof, Emma C., Deenen, Maarten J., Guchelaar, Henk-Jan, Gelderblom, Hans

“…Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper…”
Get full text

Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing by Wouden, Cathelijne H., van Rhenen, Mandy H., Jama, Wafa O.M., Ingelman‐Sundberg, Magnus, Lauschke, Volker M., Konta, Lidija, Schwab, Matthias, Swen, Jesse J., Guchelaar, Henk‐Jan

“…Pre‐emptive pharmacogenetics (PGx) testing of a panel of germline genetic variants represents a new model for personalized medicine. Clinical impact of PGx…”
Get full text

Clinical pharmacokinetics of tyrosine kinase inhibitors by van Erp, Nielka P, Gelderblom, Hans, Guchelaar, Henk-Jan

“…Summary In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs…”
Get full text

Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK by Youssef, Essra, Kirkdale, Charlotte L., Wright, David J., Guchelaar, Henk‐Jan, Thornley, Tracey

“…Aims Pharmacogenetics (PGx) in the UK is currently implemented in secondary care for a small group of high‐risk medicines. However, most prescribing takes…”
Get full text

Pharmacogenomics, a novel section in the European Journal of Human Genetics by Guchelaar, Henk-Jan

Get full text

Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? by Peruzzi, Elena, Roncato, Rossana, De Mattia, Elena, Bignucolo, Alessia, Swen, Jesse J, Guchelaar, Henk-Jan, Toffoli, Giuseppe, Cecchin, Erika

“…Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among adults and are more common in multimorbid patients, worsening clinical…”
Get full text

A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors by Yin, Anyue, Moes, Dirk Jan A.R., Hasselt, Johan G.C., Swen, Jesse J., Guchelaar, Henk‐Jan

“…Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer evolution has improved the understanding of anticancer treatment…”
Get full text

Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device by Zwart, Tom C., Gokoel, Sumit R.M., Boog, Paul J.M., Fijter, Johan W., Kweekel, Dina M., Swen, Jesse J., Guchelaar, Henk‐Jan, Moes, Dirk Jan A.R.

“…Aims Tacrolimus and mycophenolic acid dosing after renal transplantation is individualized through therapeutic drug monitoring (TDM). Home‐based dried blood…”
Get full text

The PREPARE study: benefits of pharmacogenetic testing are unclear – Authors' reply by Swen, Jesse J, Manson, Lisanne E N, Böhringer, Stefan, Pirmohamed, Munir, Guchelaar, Henk-Jan

“…If the kappa for the causality analysis is calculated with the categories definite, probable, and possible in one group, which better reflects the primary…”
Get full text

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx) by Just, Katja Susanne, Steffens, Michael, Swen, Jesse Joachim, Patrinos, George P., Guchelaar, Henk-Jan, Stingl, Julia Carolin

“…Purpose Due to the diversity within Europe, the implementation of pharmacogenomic testing in clinical practice faces specific challenges. In the context of the…”
Get full text

A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients by Sanchez‐Spitman, Anabel Beatriz, Böhringer, Stefan, Dezentjé, Vincent Olaf, Gelderblom, Hans, Swen, Jesse Joachim, Guchelaar, Henk‐Jan

“…Tamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly…”
Get full text

Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy by Marok, Fatima Zahra, Wojtyniak, Jan‐Georg, Selzer, Dominik, Dallmann, Robert, Swen, Jesse J., Guchelaar, Henk‐Jan, Schwab, Matthias, Lehr, Thorsten

“…The discovery of circadian clock genes greatly amplified the study of diurnal variations impacting cancer therapy, transforming it into a rapidly growing field…”
Get full text